nach oben

Erschienen in:

01.01.2024 | News item

Monitoring risk factors for paracetamol hepatotoxicity

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Healthcare professionals are reminded that paracetamol-related hepatotoxicity may occur at dosages within the normal therapeutic range in patients who are at increased risk, and it is therefore important to maintain awareness of any emerging or changing risk factors during treatment with paracetamol, says the Ireland Health Products Regulatory Authority (HPRA) in the HPRA Drug Safety Newsletter . …

Paracetamol: Monitoring risk factors for hepatotoxicity in patients during treatment HPRA Drug Safety Newsletter : No. 114, 21 Dec 2023. Available from: URL: https://www.hpra.ie/docs/default-source/publications-forms/newsletters/hpra-drug-safety-newsletter-edition-114.pdf?sfvrsn=5

Titel: Monitoring risk factors for paracetamol hepatotoxicity
Publikationsdatum: 01.01.2024
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-52151-0

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Monitoring risk factors for paracetamol hepatotoxicity

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Methotrexate

Crizotinib

Clonazepam/tozinameran/valproic-acid

Brimonidine

Drospirenone/ethinylestradiol

Clarithromycin